

Indications for Testing

MULTIPLE CONGENITAL ANOMALIES

NEURODEVELOPMENTAL DISORDERS

INTELLECTUAL DISABILITY AND/OR DEVELOPMENTAL DELAY

FAILURE TO THRIVE

DYSMORPHIC FEATURES

EPILEPSY SYNDROMES

EXTENSIVE DIFFERENTIAL DIAGNOSIS

PREVIOUS GENETIC TESTING UNINFORMATIVE

In the NICU/PICU

With written results as early as five days, consider Rapid Whole Genome Sequencing (rWGS) for your patients when a genetic etiology is suspected.

End Your Patient's Diagnostic Odyssey

Getting a diagnosis that explains your patient's symptoms can be life changing. Results provide treatment options, inform medical management, and open additional research opportunities so you can focus on the best care for your

EARLY DIAGNOSIS FOR PATIENT CARE

- 32% of affected individuals had changes in medical care1
- Save an average of \$12k \$15k per patient1
- On average, avoid ~525 days of hospitalization1
- 3 out of 4 families want answers and are in favor of diagnostic tests²

Am J Hum Genet.2021 Jul 1; 108(7): 1231-1238.

. Child Neurology Foundation 2020 Assessment Survey Summary



45+ YEARS OF INNOVATION



4 MILLION+ CLINICAL TESTS PERFORMED





3 THOUSAND+ TESTS OFFERED



1 MISSION EMPOWERING YOU WITH ANSWERS THAT MATTER

Baylor Genetics pioneered the history of genetic testing. Now, we're leading the way in precision medicine.

A pioneer of precision medicine for over 40 years, Baylor Genetics is a leading diagnostic genomics partner offering a full spectrum of clinically relevant genetic testing, including Whole Genome Sequencing, Whole Exome Sequencing, and focused panels. A joint venture of H.U. Group Holdings, Inc. and Baylor College of Medicine, which has the #1 NIH-funded Department of Molecular and Human Genetics, Baylor Genetics couples the fastest and most comprehensive precision diagnostics options with the support of genetic counselors to help clinicians and patients avoid a lengthy diagnostic odyssey, guide medical management, and make sure no patient with a genetic disorder gets left behind. Our test menu spans from family planning, pregnancy, neonatal and pediatric testing, oncology, and beyond.


Baylor Genetics is located in Houston's Texas Medical Center and serves clients in 50 states and 16 countries.

1.800.411.4363 BAYLORGENETICS.COM





Whole Genome Sequencing is the most advanced testing solution for detecting known and potential disease-causing variants.




WGS is the most comprehensive test available through Baylor Genetics. It analyzes up to 98% of the human genome, detecting known and potential disease-causing variants that may not be identified on more targeted genetic testing. Additionally, WGS covers both the protein-coding exons and clinically significant non-coding regions of the genome.

As the most comprehensive genetic test available, WGS captures virtually all disease-causing genetic variations including single-nucleotide variants, small insertion/deletions, copy number variants, and a comprehensive set of tandem repeat disorders. In addition, WGS also captures variants within the mitochondrial genome which further increases clinical utility.

BAYLOR GENETICS IS COMMITTED TO FINDING ANSWERS FOR YOU AND YOUR PATIENTS

To assist with providing answers, our WGS includes the following features:

 RNA sequencing (RNAseq), available as a reflex test for WGS and Rapid WGS (rWGS), can help reclassify qualifying variants



Comparison Chart

NICU / PICU

	RAPID TRIO WGS	RAPID DUO WGS	RAPID PROBAND WGS	TRIO WGS	DUO WGS	PROBAND WGS
est Code	1822	1823	1829	1800	1803	1810
arental Report Included	\otimes	\otimes	\otimes	\otimes	\otimes	\otimes
urnaround Time (TAT) reeks)	1 (starting at 5 days)†	1 (starting at 5 days) [†]	1 (starting at 5 days) [†]	3	3	3
an Elect to Receive econdary Finding(s)	\otimes	\otimes	\otimes	\otimes	\otimes	\otimes
aw Data Available	\otimes	\otimes	\otimes	\otimes	\otimes	\otimes

RNA Sequencing (RNAseq) is a reflex option to our WGS offerings to help reclassify qualifying variants.‡ Sample Requirements (if additional sample is required) TAT(days) Blood in EDTA 281 Provided as an updated (addendum) report

For rapid testing orders, please email rapidtesting@baylorgenetics.com at the time samples are sent to the laboratory. This will alert the laboratory so that the patient's sample can be accessioned quickly. To secure emails that are sent, please add "[Secure]" in the subject line.

Test Details for Whole Genome Sequencing

GENE COVERAGE

- All genes
- Single nucleotide variants/indels in coding and non-coding regions
- Copy number variants (CNV)
- Includes mitochondrial variants
- Tandem repeat disorders
- Depth/Coverage: Average 40x genome-wide
- PCR-free: Better CNV
- 2x150bp Sequencing Length: Better CNV/TRD detection and mapping for complex genomic regions
- Bioinformatic analysis performed on the newest genome build, GRCh38

METHODOLOGY

Proprietary-developed bioinformatics pipeline

TURNAROUND TIME

Written results starting at 5 days for rapid and 3 weeks for standard[†]

Sample Type Accepted

The following specimen types are accepted for all WGS orders: blood, buccal swab, cord blood, cultured skin fibroblast, extracted DNA, and saliva. For specimen requirements, please visit www.baylorgenetics.com/whole-genome-sequencing.

Additional Reporting Options

AVAILABLE ON AN OPT-IN BASIS

ACMG Secondary Findings

The American College of Medical Genetics (ACMG) has published a series of guidelines for the reporting of these types of medically actionable or secondary findings (including PMID: 34012068). These guidelines include a list of genes, which are updated occasionally, that are considered medically actionable and indicate laboratories should report pathogenic (disease-causing) and likely pathogenic findings in these genes. In accordance with an update to this policy statement (PMID: 25356965), you may choose to opt in to receive this information.

Incidental Findings

Medically actionable variants are changes found in genes known to be associated with disease but not associated with the current symptoms or clinical presentation. These variants are reported as they may cause severe, early-onset disease or may have implications for treatment and prognosis.

Potential clinically significant findings in genes with no known disease association (WGS Trio only)

Rare variants including homozygous, hemizygous, compound heterozygous, and/or de novo variants in candidate genes for which there is limited available evidence of disease association are reported as variants of uncertain significance. Relevant literature is referenced if available. These are considered research findings, and further information would be required to determine the relationship to the patient's condition.

Additional Whole Genome Sequencing testing options are available. If interested, please contact your Baylor Genetics representative or email help@baylorgenetics.com.

¶ The TAT for RNAseq is calculated from the release date of the WGS report or from date of sample receipt if an additional sample is requested by the laboratory.

^{*} Parental Report is only included for certain test codes and if the parent(s) provide a sample. For Duo Whole Genome Sequencing, only one parent is required to submit a sample.

[†] The listed TAT is dependent on sample type. Please call our Client Services team at 1-800-411-4636 for further information.

[‡] A qualified variant meets our prediction algorithm criteria (Splice AI) that RNAseq will provide additional functional information.